Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma

Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma

Purpose: Uterine carcinosarcoma (UCS) is a rare but aggressive tumor with high rates of recurrence and poor prognosis, and novel therapies are urgently needed. P53 mutations are identified in over 90% of cases, and other cell cycle alterations are commonly found indicating potential vulnerability to...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephanie Cham, Niya Xiong, Nabihah Tayob, Carolyn Krasner, Alexi A. Wright, Elizabeth K. Lee, Hannah Sawyer, Cara Mathews, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Joyce F. Liu
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Gynecologic Oncology Reports
Subjects:
Uterine carcinosarcoma
Wee1 inhibitor
TP53 mutation
Phase 2 trial
Next generation sequencing
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578925001213
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S2352578925001213

Similar Items